TG Therapeutics lifts 2026 revenue outlook to about $1 billion after Q3
TG Therapeutics reported Q3 2026 revenue of $259.9 million, including $232.6 million in US BRIUMVI sales, and raised full-year guidance from about $950 million.
Tag
Stories tagged biotech.
TG Therapeutics reported Q3 2026 revenue of $259.9 million, including $232.6 million in US BRIUMVI sales, and raised full-year guidance from about $950 million.
Regeneron reported third-quarter 2026 revenue of $5.12 billion, up 36% from a year earlier, and non-GAAP earnings of $20.07 a share, helped by higher Sanofi collaboration revenue.